Highest development stage: Phase 2 Clinical Trial (NCT04670120)

Development status: Active (as of 2023)

Mechanism of Action/Target pathogen: Active against <i>Mycobacterium </i>sp.

Additional information: Synthetic compound derived from optimization of riminophenazine analogues